Celecoxib: Not So Harmless?
Ousmane Kaba, Bouchra Chahboun, Maman Idi Chazali, Houssam Bkiyar, Brahim Housni · 2026
Read Celecoxib: Not So Harmless? by Ousmane Kaba, Bouchra Chahboun, Maman Idi Chazali, Houssam Bkiyar, Brahim Housni (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13499634.txt.
Description
Ousmane Kaba and co-authors warn in 2026 through a case report that celecoxib, a widely used pain reliever for joint pain, can trigger toxic epidermal necrolysis. The reaction is severe and potentially fatal, with the skin's surface layer dying and shedding. The drug is favoured for easier stomach tolerance, and most of its skin reactions are mild. Severe reactions of this specific type after celecoxib are poorly documented, which motivated the report alongside the drug's very wide use.
The authors set out why the reaction is so dangerous, noting its rarity at roughly two cases per million people per year and the risk carried once large skin areas are lost. Management rests on stopping the suspected drug at once, moving the patient quickly to a specialist unit, and providing intensive supportive care. Their aim is clinician awareness, since early recognition shapes survival in such reactions.
Catalog record
| CREATOR | Ousmane Kaba, Bouchra Chahboun, Maman Idi Chazali, Houssam Bkiyar, Brahim Housni |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13043 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |